T1	Participants 46 101	chronic hepatitis C resulting from intravenous drug use
T2	Participants 191 252	intravenous drug users (IVDUs) with chronic hepatitis C (CHC)
T3	Participants 519 581	treatment trial--was performed in Belgium and The Netherlands.
T4	Participants 582 656	A total of 406 previously untreated CHC patients, including 98 (24%) IVDUs
T5	Participants 1766 1782	Benelux patients
T6	Participants 1985 2040	chronic hepatitis C patients who use intravenous drugs.
